IL17A and psoriasis: Interestingly, it has recently been reported in an observation retrospective cohort study that IL-17 inhibitors appear to be more effective in decreasing systemic inflammatory markers in moderate-to-severe psoriasis in comparison to IL-23 inhibitors [12,13].